6. (Amended) A composition of Claim 1, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapodin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and

A2

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, aneoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

11. (Amended) A composition of Claim 1, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapodin A; and

A3

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

16. (Amended) A composition of Claim 1, wherein the first component comprises parthenolide; and

A4

the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

21. (Amended) A method of dietary supplementation in animals comprising administering to an animal suffering symptoms of inflammation a composition of Claim 1 and continuing said administering of the composition until said symptoms are reduced.

A5

22. (Amended) The method of Claim 21, wherein the composition is formulated in a dosage form such that said administration provides from 0.05 to 5.0 mg body weight per day of each sesquiterpene lactone species, and from 0.5 to 20.0 mg/kg bodyweight per day of each diterpene lactone species or triterpene species.

26. (Amended) The method of Claim 21, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapodin A, tenulin, confertiflorin, burrodin, psilostachyin, A, costunolide, strigol, and helenalin; and

A6

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, aneoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

27. (Amended) The method of Claim 26 wherein the composition is formulated in a dosage form such that said administration provides from 0.05 to 5.0 mg body weight per day of each

Cont. A6

sesquiterpene lactone species, and from 0.5 to 20.0 mg/kg bodyweight per day of each diterpene lactone species or triterpene species.

A7

29. (Amended) The method dietary supplementation of Claim 21, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapodin A; and

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

30. (Amended) The method of Claim 21, wherein the first component comprises parthenolide; and

the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

31. (Amended) A method of therapeutic treatment in animals comprising administering to an animal suffering symptoms of arthritis a composition of Claim 1, and continuing said administering until said symptoms are reduced.

32. (Amended) The method of Claim 31, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapodin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

33. (Amended) The method of Claim 31, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapodin A; and

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

34. (Amended) The method of Claim 31, wherein the first component comprises parthenolide; and

the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

35. (Amended) A method of therapeutic treatment comprising applying to the skin of a human suffering symptoms of acne rosacea a lotion comprising a composition is Claim 1 and continuing said administering of the composition until said symptoms are reduced.

36. (Amended) The method of Claim 35, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapodin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

37. (Amended) The method of Claim 35, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapodin A; and

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

38. (Amended) The method of Claim 35, wherein the first component comprises parthenolide; and

the second component is selected from the group consisting of andrographolide, ursolic acid, oleanolic acid, and derivatives thereof.

39. (Amended) A method of therapeutic treatment comprising applying to the skin of a human suffering symptoms of psoriasis a lotion comprising a composition of Claim 1 and continuing said administering of the composition until said symptoms are reduced.

40. (Amended) The method of Claim 39, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, melapodin A, tenulin, confertiflorin, burrodin, psilostachyin A, costunolide, strigol, and helenalin; and

the second component is selected from the group consisting of andrographolide, dehydroandrographolide, deoxyandrographolide, neoandrographolide, ursolic acid, oleanolic acid, betulin, betulinic acid, glycyrrhetinic acid, glycyrrhizic acid, triperin, and derivatives thereof.

41. (Amended) The method of Claim 39, wherein the first component is selected from the group consisting of parthenolide, encelin, leucanthin B, enhydrin, and melapodin A; and